30 closest matches · ranked by relevance
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 14.2; 4.4 Months
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Metastatic Lung Cancer · Stage IV Lung Cancer
Primary: Number of Participants With Progression-free Survival (PFS) After Completion of First Line Standard of Care Systemic Therapy — 1; 0 Participants
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants
Lung Cancer
Primary: Maximum Dose of Erlotinib When Given Together With Carboplatin, Paclitaxel, and Thoracic Conformal Radiotherapy (Phase I [Closed to Accrual as of 1/3/2008]) — 0; 0; 2 DLTs
Lung Cancer
Primary: Boost Dose Toxicity — 5 Participants
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Lung Cancer
Primary: Local Control at 2 Years — 97.6 percentage of subjects — p=0.013
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: Time to Progression — 4.63 months
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96
Extensive Stage Small Cell Lung Cancer
Primary: Percentage of Participants Alive and Progression-free (PF) at 6 Months — 30.2 Percentage of Participants
Lung Cancer
Primary: Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I) — 150 mg daily
Lung Cancer
Primary: Overall Survival — 21 months
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.35; 14.3 months
Lung Cancer
Primary: Median Progression Free Survival — 7.8 Months
Lung Cancer
Primary: Progression-free Survival at 6 Months — 60 percentage of participants
Lung Cancer
Primary: Selection of One of Two Treatment Regimens (Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel) for Further Study in a Phase III Trial, Based on Median…
Lung Cancer
Primary: Overall Survival (OS) of Nivolumab + Ipilimumab Versus Placebo In The Global Population — 9.56; 9.17 Months — p=0.3693
Lung Cancer
Primary: 18 Month Survival — 58; 54 percentage of participants
Small Cell Lung Cancer · Extensive-stage Small Cell Lung Cancer
Primary: Phase I: Confirmation of Recommended Phase II Dose — 3; 1 mg/kg dose
Lung Cancer
Primary: Progression-free Survival — 5.5; 4.4 Months
Lung Cancer
Primary: Overall Survival — 29.8 months
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Lung Cancer
Primary: Overall Survival — 6.83; 6.31 Months — p=0.506